The disclosure relates to IL-13 antagonists, in particular anti-human-IL-13 antibodies and human-IL-13-binding fragments thereof, and their use for improvement, maintenance or reduction in the rate of decline of pulmonary function in a subject with impaired pulmonary function, which may be associated with uncontrolled moderate-to-asthma, COPD or IPF.